Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab and Docetaxel in Advanced NSCLC (CR1STAL-Adaptive)
NCT06951646Phase 2Recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Mar 2026
- Primary completion
- Jul 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in non-small cell lung cancer (NSCLC), sponsored by The Second Xiangya Hospital. Started Mar 2026; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06951646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06951646.